• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    UFP Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    2/18/25 4:33:44 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care
    Get the next $UFPT alert in real time by email
    false 0000914156 0000914156 2025-02-18 2025-02-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): February 18, 2025

     

    UFP TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-12648 04-2314970
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

     

    100 Hale Street

    Newburyport, Massachusetts 01950-3504

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (978) 352-2200

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common stock   UFPT   The NASDAQ Stock Market L.L.C.

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

     

    Base Salaries

     

    At a meeting on February 11, 2025, the Compensation Committee approved increases in the base salaries of the Company’s named executive officers, effective as of the date set forth in the table below. The following table sets forth the new base salary of each of the Company’s executive officers whose base salary was adjusted by the Compensation Committee.

     

    Name and Title 2025 Base Salary Effective Date
    R. Jeffrey Bailly
    Chief Executive Officer and Chairman
    $789,000 January 1, 2025
    Mitchell C. Rock
    President
    $525,000 January 1, 2025
    Ronald J. Lataille
    Senior Vice President, Treasurer and Chief Financial Officer
    $485,000 January 1, 2025

    Christopher P. Litterio

    Senior Vice President of Human Resources and Chief Counsel

    $385,000 January 1, 2025

    Steve Cardin

    Vice President, COO

    Medtech

    $352,000 January 1, 2025

    Jason Holt

    Vice President and Chief Commercial Officer

    $352,000 January 1, 2025

      

    Stock Unit Awards

     

    Also at its February 11, 2025 meeting, the Compensation Committee approved the grant of stock unit awards to the Company’s executive officers, as indicated below. Subject to the terms of the Company’s 2003 Incentive Plan, as amended and restated (the “2003 Incentive Plan”) and the stock unit award agreement evidencing each such award, with the Company’s Chief Executive Officer, R. Jeffrey Bailly, receiving a separate form of stock unit award agreement than the other executive officers, each stock unit award provides the recipient with the right to receive one share of common stock of the Company. Recipients of the stock unit awards will have no rights as stockholders of the Company in respect thereof, including, without limitation, the right to vote or to receive dividends, until and to the extent any applicable performance objectives have been satisfied, such stock unit awards have vested, and the issuance of the shares of common stock in respect of the stock unit awards has been appropriately evidenced.

     

    Name and Title of Recipient of Stock Unit Awards Column A
    Number of “Threshold”
    Stock Unit Awards
    (No Minimum Adjusted
    Operating Income
    Requirement)
    Column B
    Number of “Target”
    Stock Unit Awards
    (Upon Attainment of
    Target Adjusted
    Operating Income)
    Column C
    Number of “Exceptional”
    Stock Unit Awards
    (Upon Attainment of
    Exceptional Adjusted
    Operating Income)
    R. Jeffrey Bailly
    Chairman and Chief Executive Officer
    11,515 5,758 5,758
    Mitchell Rock
    President
    3,817 1,909 1,909
    Ronald J. Lataille
    Senior Vice President, Treasurer and Chief Financial Officer
    3,817 1,909 1,909
    Chris Litterio
    Senior Vice President of Human Resources and Chief Counsel
    1,272 636 636
    Steve Cardin
    Vice President, COO Medtech
    636 318 318

    Jason Holt

    Vice President and Chief Commercial Officer

    1,018 509 509

     

    All stock unit awards listed in the table above are subject to time-based and continuous employment vesting requirements. The stock unit awards listed in Columns B and C are also subject to the Company meeting certain financial performance objectives (the “Performance Objectives”). The Compensation Committee shall determine whether and to what extent any of the Performance Objectives have been achieved by the Company. Such determination is currently expected to take place in February 2025. Assuming achievement of the applicable Performance Objectives, one-third of the stock unit awards listed in Columns A, B, and C above shall vest on March 1, 2026, one-third shall vest on March 1, 2027 and one-third shall vest on March 1, 2028, provided that the recipient remains continuously employed by the Company through each such vesting date.

     

     

     

    Any unvested stock unit awards shall terminate upon the cessation of a recipient’s employment with the Company. Notwithstanding the foregoing and only with respect to the award to Mr. Bailly, subject to the terms of Mr. Bailly’s employment agreement dated October 8, 2007, as amended (the “CEO Employment Agreement”), and the stock unit award agreement evidencing Mr. Bailly’s award, in the event that Mr. Bailly’s employment ceases without “cause” or for “good reason” (as such terms are defined in the CEO Employment Agreement), Mr. Bailly shall be entitled to receive shares that, but for such cessation of employment, would have otherwise been issued to Mr. Bailly pursuant to the terms of the stock unit awards listed in Columns A, B, and C above, notwithstanding such cessation of employment.

     

    In the event of a change in control of the Company (as defined in the 2003 Incentive Plan), any unvested stock unit awards listed in each of Columns A, B, and C above shall become fully vested as of the effective date of such change in control, provided that the recipient has been continuously employed by the Company through the date immediately prior to the effective date of such change in control, and, with respect to the stock unit awards listed in Columns B and C above, subject to achievement of any applicable Performance Objectives prior to the effective date of such change in control.

     

    The above description of the stock unit awards is qualified in its entirety by reference to the text of the CEO stock unit award agreement or the stock unit award agreement evidencing such awards, as applicable, copies of the forms of which are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated herein in their entirety by reference.

     

    2025 Chief Executive Officer’s Performance Bonus Plan

     

    Also at its February 11, 2025 meeting, the Compensation Committee approved a 2025 cash bonus plan for Mr. Bailly that included corporate financial performance targets and individual performance goals. This award was made under and pursuant to the 2003 Incentive Plan. The overall targeted bonus established under this plan was $828,450 (105% of Mr. Bailly’s 2025 base salary), with a maximum amount of $1,656,900 (two times Mr. Bailly’s target bonus). The actual bonus award, if any, will be determined based upon the level of achievement of the established performance targets and goals as determined by the Compensation Committee.

     

    2025 Named Executive Officer Cash Bonus Plan

     

    Also at its February 6, 2025 meeting, the Compensation Committee approved the corporate financial performance targets and individual performance goals for a 2025 cash bonus plan for Messrs. Rock, Lataille, Litterio, Cardin and Holt. The target amounts of such cash bonuses range from 40% to 65% of base salary for each of the officers. The actual amount of each cash bonus, if any, will be subject to increase or decrease at the discretion of the Compensation Committee.

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Number   Description
    10.1   Form of 2025 CEO Stock Unit Award Agreement.
    10.2   Form of 2025 Stock Unit Award Agreement.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

      

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Dated: February 18, 2025 UFP TECHNOLOGIES, INC.  
           
           
           
      By: /s/ Ronald J. Lataille  
        Ronald J. Lataille, Chief Financial
        Officer and Senior Vice President

     

     

     

     

     

    Get the next $UFPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UFPT

    DatePrice TargetRatingAnalyst
    3/28/2025Mkt Perform
    Raymond James
    7/17/2024$344.00 → $392.00Buy
    Lake Street
    3/20/2024Market Outperform
    CJS Securities
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    12/21/2022$124.00Buy
    Lake Street
    6/22/2022$110.00Buy
    Lake Street
    11/19/2021$81.00Buy
    Colliers Securities
    More analyst ratings

    $UFPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by UFP Technologies Inc.

      SC 13G - UFP TECHNOLOGIES INC (0000914156) (Subject)

      11/13/24 9:58:23 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by UFP Technologies Inc. (Amendment)

      SC 13G/A - UFP TECHNOLOGIES INC (0000914156) (Subject)

      3/8/24 3:02:25 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by UFP Technologies Inc.

      SC 13G - UFP TECHNOLOGIES INC (0000914156) (Subject)

      2/13/24 5:16:09 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care

    $UFPT
    Leadership Updates

    Live Leadership Updates

    See more
    • UFP Technologies Acquires AQF Medical

      NEWBURYPORT, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, today announced the acquisition of AQF Limited ("AQF Medical"). Headquartered in Navan, Ireland with additional joint venture operations in Singapore, AQF Medical develops and manufactures custom-engineered foam and thermoplastic components used in a wide range of medical devices and packaging. "We are excited about the addition of AQF Medical, our fourth acquisition in the past few months," said R. Jeffrey Bailly, Chairman and CEO of UFP Technologies.

      8/26/24 9:00:00 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • UFP Technologies Acquires Marble Medical

      NEWBURYPORT, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, today announced the acquisition of Marble Medical. Founded in 1988 and headquartered in Tallahassee, FL, Marble Medical develops and manufactures adhesive based medical components and single-use devices. "Adding Marble Medical's adhesives expertise is a great complement to our surgical robot drapes and stick to skin device platforms," said R. Jeffrey Bailly, chairman and CEO of UFP Technologies. "Marble Medical is a 3M Preferred Converter, and along wi

      7/16/24 4:05:00 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • Chimerix Appoints Marc D. Kozin to Board of Directors

      DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo

      3/21/24 7:00:00 AM ET
      $CMRX
      $UFPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $UFPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Vice President Holt Jason covered exercise/tax liability with 462 shares, decreasing direct ownership by 6% to 7,848 units (SEC Form 4)

      4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

      3/5/25 8:02:14 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • Vice President Cardin Steve covered exercise/tax liability with 623 shares, decreasing direct ownership by 10% to 5,623 units (SEC Form 4)

      4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

      3/5/25 7:59:35 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • Senior Vice President Litterio Christopher P. covered exercise/tax liability with 921 shares, decreasing direct ownership by 6% to 14,058 units (SEC Form 4)

      4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

      3/5/25 7:54:06 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care

    $UFPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UFP Technologies Announces Record Q1 Results

      NEWBURYPORT, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions primarily for the medical market, today reported net income of $17.2 million or $2.21 per diluted common share outstanding for its first quarter ended March 31, 2025, compared to net income of $12.7 million or $1.64 per diluted common share outstanding for the first quarter of 2024. Net Sales for the first quarter were $148.1 million compared to 2024 first quarter sales of $105.0 million. Throughout this news release, reference is made to non-GAAP measures including organic sales growth, adjusted operating income, adjusted SG&A, adjusted n

      5/6/25 9:00:56 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • UFP Technologies to Report First Quarter 2025 Financial Results on May 6, 2025

      NEWBURYPORT, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), an innovative designer and custom manufacturer of components for medical devices, sterile packaging, and other highly engineered products, today announced the Company plans to report financial results for the first quarter ended March 31, 2025 on May 6, 2025 prior to market open. The Company will hold a conference call to discuss results the same day at 10:00 AM Eastern time. Conference Call Information:Date: Tuesday, May 6, 2025Time: 10:00 AM Eastern TimeParticipants may join the call using the following dial-in numbers: Toll-Free: 1-888-243-4451International: 1-412-542-4135 A live webcast of t

      4/30/25 9:00:43 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • UFP Technologies to Present and Host Investor Meetings at the KeyBanc Capital Healthcare Forum

      NEWBURYPORT, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), an Innovative designer and custom manufacturer of components, subassemblies, products, and packaging primarily for the medical market, today announced that Chairman and Chief Executive Officer R. Jeffrey Bailly and Chief Financial Officer Ron Lataille will participate in the upcoming KeyBanc Capital Markets Healthcare Forum to be held virtually on March 18, 2025. UFP's presentation is scheduled to begin at 10:30 AM ET. About UFP Technologies, Inc.UFP Technologies is a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engine

      3/17/25 9:00:01 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care

    $UFPT
    Financials

    Live finance-specific insights

    See more
    • UFP Technologies Announces Record Q1 Results

      NEWBURYPORT, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions primarily for the medical market, today reported net income of $17.2 million or $2.21 per diluted common share outstanding for its first quarter ended March 31, 2025, compared to net income of $12.7 million or $1.64 per diluted common share outstanding for the first quarter of 2024. Net Sales for the first quarter were $148.1 million compared to 2024 first quarter sales of $105.0 million. Throughout this news release, reference is made to non-GAAP measures including organic sales growth, adjusted operating income, adjusted SG&A, adjusted n

      5/6/25 9:00:56 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • UFP Technologies to Report First Quarter 2025 Financial Results on May 6, 2025

      NEWBURYPORT, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), an innovative designer and custom manufacturer of components for medical devices, sterile packaging, and other highly engineered products, today announced the Company plans to report financial results for the first quarter ended March 31, 2025 on May 6, 2025 prior to market open. The Company will hold a conference call to discuss results the same day at 10:00 AM Eastern time. Conference Call Information:Date: Tuesday, May 6, 2025Time: 10:00 AM Eastern TimeParticipants may join the call using the following dial-in numbers: Toll-Free: 1-888-243-4451International: 1-412-542-4135 A live webcast of t

      4/30/25 9:00:43 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • UFP Technologies to Report Fourth Quarter and Year-end 2024 Results on February 25, 2025

      NEWBURYPORT, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), an innovative designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today announced that the Company plans to report results for the fourth quarter and year-ended December 31, 2024, on Tuesday, February 25th. About UFP Technologies, Inc. UFP Technologies is an innovative designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. UFP is an important link in the medical device supply chain and a valued outsource partner to man

      2/19/25 9:00:38 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care

    $UFPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on UFP Technologies

      Raymond James initiated coverage of UFP Technologies with a rating of Mkt Perform

      3/28/25 8:21:18 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • Lake Street reiterated coverage on UFP Technologies with a new price target

      Lake Street reiterated coverage of UFP Technologies with a rating of Buy and set a new price target of $392.00 from $344.00 previously

      7/17/24 8:57:19 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • CJS Securities initiated coverage on UFP Technologies

      CJS Securities initiated coverage of UFP Technologies with a rating of Market Outperform

      3/20/24 9:43:53 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care

    $UFPT
    SEC Filings

    See more
    • SEC Form 144 filed by UFP Technologies Inc.

      144 - UFP TECHNOLOGIES INC (0000914156) (Subject)

      5/8/25 3:49:36 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • UFP Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UFP TECHNOLOGIES INC (0000914156) (Filer)

      5/7/25 8:39:37 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by UFP Technologies Inc.

      DEF 14A - UFP TECHNOLOGIES INC (0000914156) (Filer)

      4/30/25 12:05:31 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care

    $UFPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Lataille Ronald J bought $91,636 worth of shares (400 units at $229.09), increasing direct ownership by 3% to 15,031 units (SEC Form 4)

      4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

      2/27/25 3:57:17 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Lataille Ronald J

      4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

      11/13/23 11:09:49 AM ET
      $UFPT
      Medical/Dental Instruments
      Health Care
    • Rock Mitchell bought $27,522 worth of shares (198 units at $139.00), increasing direct ownership by 0.74% to 27,086 units (SEC Form 4)

      4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

      11/9/23 5:21:17 PM ET
      $UFPT
      Medical/Dental Instruments
      Health Care